Royce & Associates’s TherapeuticsMD TXMD Stock Holding History

Royce & Associates’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,000	Closed	-$191K	–	1188
2018 Q4	$191K	Buy	+1,000	New	+$244K	﹤0.01%	980

Other funds holding TXMD

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Royce & Associates's TXMD Position: Q1 2019 in Review

Royce & Associates sold out of TherapeuticsMD (TXMD) in Q1 2019, closing a stake of 1,000 shares — an estimated $191K sold.

Royce & Associates first reported a position in TXMD in Q4 2018 and held it in 1 quarter. The position peaked at $191K in Q4 2018. 146 funds tracked by Wall St. Rank hold TXMD as of Q1 2019.

Royce & Associates reported no remaining TherapeuticsMD position as of Q1 2019 after selling out during the quarter.
Royce & Associates sold 1,000 TherapeuticsMD shares in Q1 2019, an estimated $191K.
Royce & Associates first reported a position in TherapeuticsMD in Q4 2018 and held it in 1 quarter.
Royce & Associates's TherapeuticsMD position peaked at $191K in Q4 2018.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2019.

Based on Royce & Associates's 13F filing for Q1 2019, filed 9 May 2019.